The in-house oral oncolytic pharmacy of Florida Cancer Specialists & Research Institute (FCS), known as Rx To Go, has been accredited by the National Association of Boards of Pharmacy® (NABP®) for both specialty pharmacy and digital pharmacy practice.
Medical oncologist James Reeves, MD, a member of the Florida Cancer Specialists & Research Institute (FCS) Clinical Research Team, is co-author of an abstract entitled “Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).”
Dr. Hugo Davila, who practices urology and minimally-invasive surgery with Florida Healthcare Specialists (FHS), is the lead author of a new study entitled “Evaluation of the Pubocervical Fascia with 3-Dimensional Endovaginal Ultrasonography (EVUS) and Correlation with Intraoperative Findings during Robotic Sacrocervicopexy.”
Lucio Gordan MD, President and Managing Physician of Florida Cancer Specialists & Research Institute (FCS) and Michael Diaz, MD, Assistant Managing Physician of FCS, are two of the authors of a comprehensive and detailed review on the advisability and efficiency of the current reimbursement methodology in use for Medicare Part B.
Florida Cancer Specialists & Research Institute (FCS) physicians and senior leaders are the co-authors of 32 research studies that will be presented at the American Society of Clinical Oncology (ASCO®) 2021 Annual Meeting being held June 4 – 8, 2021.
Medical oncologist Syed Zafar MD, who practices at three Florida Cancer Specialists & Research Institute (FCS) locations in Lee County, is co-author of a new study entitled “Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.”
Julio Lautersztain, MD, medical oncologist who practices at Florida Cancer Specialists & Research Institute (FCS) locations in Tampa and Brandon, is co-author of a new study entitled “Novel mechanism of hereditary pyropoikilocytosis phenotype due to co‐inheritance of β globin and α spectrin mutations.”
Pareshkumar Patel, MD, medical oncologist with Florida Cancer Specialists & Research Institute (FCS), is the recipient of the 2021 FLASCO Advocate of the Year Award.
FCS Top News Updates
FCS Signals Next Chapter of Growth With Planned Leadership Transition and Focus on Innovation
Florida Cancer Specialists & Research Institute Oral Oncolytic Pharmacy Earns Dual NABP Pharmacy AccreditationsThe in-house oral oncolytic pharmacy of Florida Cancer Specialists & Research Institute (FCS), known as Rx To Go, has been accredited by the National Association of Boards of Pharmacy® (NABP®) for both specialty pharmacy and digital pharmacy practice.
James Reeves, MD Co-Authors Abstract Evaluating Abemaciclib Combined with Adjuvant Endocrine Therapy in Patients with High Risk Early Breast CancerMedical oncologist James Reeves, MD, a member of the Florida Cancer Specialists & Research Institute (FCS) Clinical Research Team, is co-author of an abstract entitled “Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC).”
Hugo Davila, MD Is Lead Author of Study Evaluating the Pubocervical Fascia in Female Pelvic Organ ProlapseDr. Hugo Davila, who practices urology and minimally-invasive surgery with Florida Healthcare Specialists (FHS), is the lead author of a new study entitled “Evaluation of the Pubocervical Fascia with 3-Dimensional Endovaginal Ultrasonography (EVUS) and Correlation with Intraoperative Findings during Robotic Sacrocervicopexy.”
Lucio Gordan, MD and Michael Diaz, MD Are Co-Authors of In-Depth Review on Medicare Part B ReimbursementLucio Gordan MD, President and Managing Physician of Florida Cancer Specialists & Research Institute (FCS) and Michael Diaz, MD, Assistant Managing Physician of FCS, are two of the authors of a comprehensive and detailed review on the advisability and efficiency of the current reimbursement methodology in use for Medicare Part B.
Florida Cancer Specialists & Research Institute Studies Featured at ASCO® 2021 Annual MeetingFlorida Cancer Specialists & Research Institute (FCS) physicians and senior leaders are the co-authors of 32 research studies that will be presented at the American Society of Clinical Oncology (ASCO®) 2021 Annual Meeting being held June 4 – 8, 2021.
Syed Zafar, MD Co-Authors Study on Adjuvant Nivolumab in Esophageal/Gastroesophageal Junction CancerMedical oncologist Syed Zafar MD, who practices at three Florida Cancer Specialists & Research Institute (FCS) locations in Lee County, is co-author of a new study entitled “Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.”
Julio Lautersztain, MD Co-Authors Study on Novel Co-Inheritance of Beta Globin and Spectrin MutationsJulio Lautersztain, MD, medical oncologist who practices at Florida Cancer Specialists & Research Institute (FCS) locations in Tampa and Brandon, is co-author of a new study entitled “Novel mechanism of hereditary pyropoikilocytosis phenotype due to co‐inheritance of β globin and α spectrin mutations.”
Florida Cancer Specialists & Research Institute Medical Oncologist Paresh Patel, MD Named 2021 FLASCO “Advocate of the Year”Pareshkumar Patel, MD, medical oncologist with Florida Cancer Specialists & Research Institute (FCS), is the recipient of the 2021 FLASCO Advocate of the Year Award.